| Previous Close | 7.51 |
| Open | 7.18 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 7.18 - 7.18 |
| 52 Week Range | 5.45 - 20.00 |
| Volume | 875 |
| Avg. Volume | 2,466 |
| Market Cap | 131.186M |
| Beta (3Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.41 |
LYON, France and CAMBRIDGE, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells. The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer. TRYbeCA1 is expected to enroll approximately 500 patients with second-line metastatic pancreatic cancer at more than 120 clinical sites in Europe and the United States.
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells. The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer. TRYbeCA1 is expected to enroll approximately 500 patients with second-line metastatic pancreatic cancer at more than 120 clinical sites in Europe and the United States.
Conference call and webcast on Tuesday, May 7 at 2:30 pm CET/8:30 am EDT TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new ...
LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...
Lyon (France), March 2, 2019 - ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances ...
LYON, France, April 02, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers ...
LYON, France, April 02, 2019 -- Article 223-16 of general regulation of French Autorité des.
Results support the potential for combination of erymethionase with checkpoint inhibition LYON, France and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ...
LYON, France, March 29, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative by encapsulating therapeutic ...
LYON, France, March 29, 2019 -- ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative by encapsulating.
LYON, France, March 12, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C ...
LYON, France, March 12, 2019 -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon - France Listing markets: Euronext Paris from Euronext.
Conference call and webcast on Tuesday, March 12 th at 1:30 pm CET/8:30 am EDT TRYbeCA1, a pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, now actively enrolling patients TRYbeCA2, ...
LYON, France and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by ...
LYON, France and CAMBRIDGE, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by ...
LYON, France, March 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...
LYON, France, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C ...